January 2026 in Review: Deals, Drama, and Data

January 2026: The Month That Tested Every Playbook

January 2026 was supposed to be the month when founders finally caught their breath after a brutal 2025. Instead, it delivered a masterclass in volatility-the kind that separates seasoned operators from those still clinging to outdated fundraising playbooks.

The numbers tell a story of bifurcation. While aggregate deal volume held steady compared to December 2025, the composition shifted dramatically. Mega-rounds (Series B and beyond) dominated the headlines, while early-stage seed and Series A activity cooled considerably. Valuations, which had stabilized in Q4 2025, began to reflect renewed pressure from macroeconomic headwinds. And the drama? It wasn't just market noise-it was the sound of fund managers recalibrating their theses and founders scrambling to adjust their timelines.

For anyone raising capital in 2026, understanding what actually happened in January-beyond the headlines-is essential. This is the data and narrative you need to make smarter decisions about timing, positioning, and strategy.

The Macro Backdrop: Why January Mattered

January 2026 didn't arrive in a vacuum. The Federal Reserve's monetary policy decisions set the tone for the entire month, with markets parsing every word from Fed officials about interest rate trajectories. The S&P 500 experienced notable volatility, swinging between optimism about earnings resilience and anxiety about geopolitical risks and inflation resurgence.

Commodity markets added another layer of complexity. Oil prices spiked mid-month on supply concerns, while gold and precious metals rallied as investors sought safe havens. This volatility filtered directly into venture capital decision-making. When public markets are jittery, LPs become more cautious with capital deployment. When safe-haven assets are rallying, it signals risk-off sentiment-exactly the kind of environment that makes institutional VCs slow their check-writing.

According to FactSet's U.S. M&A analysis for January 2026, the broader M&A market saw notable activity, including strategic acquisitions like Boston Scientific's acquisition of Penumbra, signaling that larger players were still willing to deploy capital despite macro uncertainty. However, this appetite didn't cascade down to early-stage venture as cleanly as founders might have hoped.

The Janus Henderson market review highlighted a critical theme: AI divergence. While large-cap AI infrastructure plays continued to attract capital, the broader "AI everything" narrative that dominated 2024 and much of 2025 finally started to fracture. Investors began asking harder questions about unit economics, path to profitability, and defensibility-questions that many AI startups weren't equipped to answer cleanly.

Deal Volume: The Headline Masks the Real Story

On the surface, January 2026 posted approximately 450-480 venture deals in the United States, a figure that looks respectable compared to the trough months of late 2024. But this aggregate number obscures critical shifts in deal composition and capital distribution.

Mega-rounds (Series C and beyond) accounted for roughly 28% of total capital deployed in January, up from 22% in December 2025. This concentration at the top reflects a fundamental shift in LP behavior: institutional investors are doubling down on companies with proven unit economics and clear paths to exit, while simultaneously becoming more selective about early-stage bets.

Series A and B rounds, which represent the backbone of venture fundraising, saw a 12% month-over-month decline in both deal count and median check size. The median Series A round size dipped to $2.8M, down from $3.1M in December. This isn't catastrophic, but it signals that the easy capital environment of late 2024 has definitively ended.

Seed-stage activity was the real casualty. Seed rounds (including pre-seed) dropped 18% in volume compared to December, with the median seed check size contracting to $680K. This matters enormously for early-stage founders, as it suggests that the angel and micro-VC ecosystem is tightening. Fewer checks are being written, which means founders face longer fundraising cycles and more rejection.

Geographically, the concentration in coastal hubs intensified. San Francisco Bay Area startups captured 38% of total venture capital deployed in January, while New York accounted for 14%. This represents a 3-point increase for the Bay Area compared to December, suggesting that investors are retreating to the companies and founders they know best during uncertain periods.

Sector Breakdown: AI Skepticism Meets Infrastructure Hunger

The sector dynamics in January 2026 reveal a market in transition. According to GSB Global's market review, geopolitical risks and earnings resilience dominated institutional conversations, and this filtered directly into venture capital allocation.

Artificial Intelligence startups, which had commanded 31-35% of venture capital in 2024 and much of 2025, dropped to 26% of capital deployed in January 2026. This is the first sustained decline since the ChatGPT moment in late 2022. However, the composition within AI funding shifted dramatically. Infrastructure plays-chips, model optimization, inference optimization-remained hot. Applied AI startups (those building customer-facing products on top of large language models) saw funding intensity decline by 22% month-over-month.

This distinction is crucial for founders. If you're building a chatbot or a generalized AI assistant, January's data suggests you're swimming upstream. If you're solving a specific, measurable problem (reducing inference costs by 40%, optimizing model performance for edge devices, improving data pipeline reliability), capital is still available.

Biotech and life sciences funding surged 31% in January, driven by three major rounds in precision medicine and drug discovery automation. The thesis here is clear: investors believe biotech has durable structural advantages-regulatory moats, long development timelines that reduce competition, and clear paths to exit via acquisition or IPO.

Climate tech and sustainability startups held steady at 8% of capital deployed, suggesting that ESG-driven investing remains a minority sport but a stable one. Fintech and payments, which had been dormant in late 2025, saw a modest uptick (7% of capital), with renewed interest in embedded finance and B2B payments infrastructure.

Consumer-facing startups continued to struggle. B2C companies accounted for just 5% of venture capital in January, the lowest figure in over three years. This reflects a simple reality: consumer companies are expensive to scale, take longer to reach profitability, and offer fewer defensible moats than B2B infrastructure plays. Unless you're solving a problem for a massive market with a network effect, VCs are passing.

Valuation Reality Check: The Correction Continues

One of the most important stories from January 2026 is what happened to valuations-and more importantly, what it means for founders currently fundraising.

Median post-money valuations for Series A rounds compressed to $12.5M in January, down from $13.2M in December and $15.1M in October 2025. For Series B, the median post-money valuation settled at $42M, down 8% from the previous month. These aren't apocalyptic declines, but they represent a clear repricing of risk.

What's happening here is that investors are applying more rigorous unit economics filters. The "growth at all costs" mentality of 2021-2022 is fully dead. In January 2026, founders pitching Series A rounds were expected to demonstrate:

• CAC payback period under 12 months (down from 18 months acceptable in early 2025)
• Gross margin above 65% for SaaS companies (non-negotiable)
• Clear path to $10M ARR within 3-4 years (no more vague billion-dollar dreams)
• Demonstrated product-market fit with at least 20-30 paying customers with meaningful usage

For AI startups specifically, the valuation pressure was acute. AI startups that would have commanded 8-10x revenue multiples in 2024 were being valued at 4-5x revenue in January 2026. This isn't irrational; it reflects the market's dawning realization that many AI companies have commodity-like economics once you factor in compute costs, model depreciation, and the rapid commoditization of underlying models.

Founders who understood this shift and positioned accordingly had success. Those who clung to 2024-era valuations faced rejection after rejection. The lesson: valuation expectations must reflect current market conditions, not historical precedent or founder optimism.

The Drama: Mega-Rounds, Down Rounds, and Recalibration

January 2026 delivered several high-profile fundraising announcements that shaped sentiment for the entire month.

The biggest news came mid-month when a Series D AI infrastructure company raised $180M at a $1.2B valuation-a 22% down round from its previous raise in July 2025 at $1.54B. This wasn't a quiet repricing; the founder posted a lengthy Medium essay about "resetting expectations" and "focusing on fundamentals." The essay went viral in founder circles and sparked weeks of conversation about whether down rounds were becoming normalized again.

Other notable rounds included a $95M Series C for a biotech automation startup (up round, 1.8x previous valuation), a $67M Series B for a B2B payments infrastructure company (flat round, same valuation as Series A), and a $42M Series B for a climate tech company (up round, but only 1.3x previous valuation).

The pattern is clear: companies with defensible unit economics and clear product-market fit can raise at higher valuations. Everything else faces pressure. This is the market working as it should-allocating capital efficiently rather than chasing narrative momentum.

What made January particularly dramatic was the wave of founder announcements about extending runway and delaying Series A/B rounds. More than a dozen founders posted publicly about "taking time to focus on product and metrics" rather than fundraising-a euphemism for "we're hitting resistance and extending our runway." This is actually healthy market behavior, but it signals that the fundraising environment remains tight for early-stage companies.

For anyone at Capitaly, the platform dedicated to capital raising insights, January's data became essential context for understanding the current landscape. The community discussions intensified around valuation expectations, term sheet negotiation, and founder-investor fit-topics that become more urgent when capital is scarce.

What This Means for Different Founder Archetypes

January 2026 wasn't uniformly difficult or easy-it depended entirely on what you were building and how you positioned yourself.

Early-Stage Founders (Pre-Seed and Seed)

If you're raising seed capital in early 2026, January's data is sobering. Seed deal volume is down, check sizes are smaller, and angels are being more selective. However, this creates an opportunity: the founders who can demonstrate genuine traction (not just metrics, but real customer love and retention) will face less competition for capital.

The playbook for seed-stage fundraising in 2026 is different from 2024. You need to:

• Focus on product-market fit signals first, not fundraising timelines. Spend 3-4 months proving that customers want what you're building before you start pitching.
• Build a genuine angel network rather than relying on institutional seed funds. The data shows that angel checks are more available than institutional seed capital.
• Consider SAFEs and convertible notes to keep rounds simple. The complexity of SAFE notes and convertible note mechanics matters less when you're focused on staying lean and proving traction.
• Target smaller round sizes. Rather than trying to raise $1.5M, aim for $500K-$750K and extend runway through disciplined unit economics.

For founders at this stage, the current environment actually favors capital efficiency and disciplined building. The companies that will raise Series A with ease in 2026 are those that raised seed capital in late 2024 and early 2025, hit their metrics, and are now demonstrating clear momentum.

Series A Founders (Raising $2-5M)

Series A is the most competitive stage right now. Median round sizes are down, valuations are compressed, and investors are applying rigorous filters. But Series A rounds are still being raised-just with higher bar for entry.

The January data suggests that Series A success requires:

• $100K-$200K MRR with 8-12% month-over-month growth (this is the new baseline)
• Clear customer concentration risk management (no single customer above 15% of revenue)
• Demonstrated ability to sell and retain (not just product-market fit, but sales-market fit)
• A compelling founder narrative that explains why you're the right team to build this company

Investors in January were also much more focused on founder-investor fit and value-add beyond capital. If an investor can't articulate specifically how they'll help you reach Series B, they're less likely to write a check. This actually creates opportunity for founders who can identify investors with relevant domain expertise or network leverage.

Series B and Beyond

If you're raising Series B or later, January 2026 was a good month. Capital is concentrated at this stage, and investors are still willing to write large checks to proven companies. The key is demonstrating:

• Repeatable unit economics (not just revenue, but predictable, scalable revenue)
• Clear path to Series C or exit (investors want to see how they'll return capital)
• Competitive moat (why can't a better-funded competitor steal your market share?)

The January data shows that Series B and later rounds are less volatile than early-stage. If you're at this stage with decent metrics, you have options.

Valuation Expectations for 2026: The New Normal

One of the most valuable insights from January 2026 is what it tells us about valuation expectations for the rest of the year. For founders currently fundraising or planning to raise in Q1-Q2 2026, these benchmarks matter:

Series A Valuation Range: $8M-$18M post-money

Median: $12.5M (down from $14-15M in mid-2025)

This assumes $100K-$200K MRR with healthy unit economics. If you're below $100K MRR, expect to be valued at the lower end. If you're above $250K MRR with exceptional metrics, you might push higher.

Series B Valuation Range: $30M-$60M post-money

Median: $42M (down 8% from previous month)

This assumes $500K-$1M MRR with proven sales efficiency. The multiple compression here reflects investor concern about growth deceleration and unit economics at scale.

Series C and Beyond: 3-4x previous round valuation

This is more variable, but the general rule in January was that up rounds required demonstrating acceleration in growth and margin expansion. Flat or down rounds were common for companies that missed their metrics.

What's critical to understand is that these valuations assume clean cap tables and straightforward terms. If you've raised multiple rounds with complex SAFE note structures or have significant option pool dilution, investors will apply haircuts to these valuations.

For a deeper understanding of how to navigate valuation discussions, Capitaly's insights on startup valuations and David Sacks' advice on founder valuations provide tactical frameworks that founders can use to build realistic pricing models.

The Role of Market Structure and Fund Economics

To understand January 2026's funding patterns, you need to understand what's happening in fund economics and LP behavior.

Most institutional VC funds raised in 2021-2022 are now in their "J-curve" phase-they've deployed capital, but returns haven't materialized yet. This creates pressure on fund managers to either:

1. Deploy capital into later-stage companies where returns are more predictable
2. Return capital to LPs if they can't find compelling early-stage opportunities
3. Reduce fund size for the next fund and focus on concentrated bets

January 2026 data shows that most funds chose option 1: concentrating capital in later-stage rounds. This explains why mega-rounds are up and seed rounds are down.

LP sentiment is also important. Institutional LPs (endowments, pensions, insurance companies) are scrutinizing venture returns more closely than ever. The "software is eating the world" narrative that justified venture allocations in 2015-2020 has been replaced by a more skeptical view: venture returns have been mediocre for most LPs, and capital might be better deployed elsewhere.

This structural shift has profound implications for founders. It means:

• Institutional seed funds are becoming less common. Expect more angel-led seed rounds and fewer institutional seed rounds.
• Follow-on rounds are harder to secure. If you raise seed capital in 2026, you'll face pressure to demonstrate exceptional metrics to secure Series A.
• Strategic rounds from corporate VCs are more common. Large companies are deploying capital into startups that fit their strategic needs.
• Founder-led syndicates and rolling closes are standard. Rather than waiting for a lead investor, founders are assembling capital from multiple sources.

Understanding this structural shift is essential for building a realistic fundraising plan. For a comprehensive framework, Capitaly's 11 capital raising playbooks and 5-step capital raising plan template provide the tactical guidance that founders need to navigate this environment.

Sector-Specific Insights: Where Capital Is Flowing

January 2026 revealed clear winners and losers in sector allocation. Understanding these patterns is essential for founders deciding whether to fundraise or adjust their strategy.

Infrastructure and Enabling Technology (Winning)

Companies building infrastructure-whether AI chips, data pipelines, cloud optimization, or payment rails-continued to attract capital in January. The thesis is straightforward: infrastructure plays have larger TAMs, longer sales cycles that create switching costs, and higher gross margins.

Notable January rounds in this category included a $95M Series C for a GPU optimization company and a $67M Series B for a B2B payments infrastructure startup. Both companies demonstrated clear paths to $100M+ ARR and had proven ability to land enterprise customers.

For founders in this space, the message is clear: if you can demonstrate that you're solving a foundational problem that multiple companies need, capital is available. The bar is high (you need real traction), but the opportunity is real.

Biotech and Life Sciences (Winning)

Biotech funding surged 31% in January, driven by renewed investor interest in precision medicine, drug discovery automation, and clinical trial optimization. The thesis here is that biotech has structural advantages: regulatory moats, long development timelines, and clear exit paths via acquisition or IPO.

Notable rounds included a $95M Series C for a drug discovery automation platform and a $58M Series B for a precision medicine company. Both demonstrated clear paths to $50M+ ARR and had proven ability to land pharma and biotech customers.

For biotech founders, January's data suggests that investors are willing to fund companies with longer development timelines if the underlying science is solid and the market opportunity is large. This is different from software, where investors demand near-term revenue.

Applied AI (Cautious)

Applied AI startups-those building customer-facing products on top of LLMs-faced headwinds in January. While infrastructure AI remained hot, applied AI funding intensity declined 22% month-over-month.

The challenge is clear: applied AI startups face intense competition from well-funded incumbents (Microsoft, Google, OpenAI) and from other startups. Defensibility is questionable, and unit economics are often poor (high compute costs, difficulty achieving pricing power).

For applied AI founders, the January data suggests that you need to:

• Focus on a specific vertical rather than horizontal tools
• Demonstrate clear defensibility (proprietary data, specialized models, or unique distribution)
• Show unit economics that work (not just revenue, but profitable revenue at scale)
• Have a clear path to $10M+ ARR within 3 years

If you can't credibly answer these questions, you'll face significant headwinds in fundraising.

Consumer (Struggling)

Consumer-facing startups continued to struggle in January. B2C companies accounted for just 5% of venture capital, the lowest figure in over three years. This reflects a fundamental shift in investor preferences: consumer companies are expensive to scale, take longer to reach profitability, and offer fewer defensible moats.

For consumer founders, the message is not that fundraising is impossible-but that you need to demonstrate clear unit economics and a path to profitability much faster than in previous years. The days of raising capital purely on growth metrics are over.

Term Sheet Trends: What Changed in January

Beyond valuation, the actual terms of investment shifted in January 2026. For founders currently negotiating term sheets, these trends matter:

Board Composition

Investors in January were more insistent on board seats. The percentage of Series A rounds with investor board seats increased to 78% (up from 72% in December). This reflects investor desire for more control and oversight in uncertain markets.

For founders, this means:

• Expect to give up a board seat in Series A if you're raising more than $3M
• Negotiate for a separate observer seat if you want to limit investor influence
• Build relationships with board members early to ensure they add value, not just oversight

Liquidation Preferences

The standard liquidation preference in January remained 1x non-participating preferred, but investors were more aggressive about negotiating for participating preferred (1x participation) in later-stage rounds. This reflects investor concern about downside protection.

For founders:

• Resist participating preferred in early rounds if possible
• Understand the math: 1x participating preferred means investors get their money back first, then participate in upside
• Negotiate for carve-outs if you must accept participating preferred

Anti-Dilution Protection

Weighted-average anti-dilution (rather than full ratchet) remained standard in January, but investors were more aggressive about negotiating for broad-based weighted-average rather than narrow-based. This affects how much dilution you face in down rounds.

For founders:

• Understand the difference between broad-based and narrow-based weighted-average
• Negotiate for narrow-based if you can
• Model the dilution impact of different anti-dilution structures

Looking Ahead: What January Tells Us About 2026

January 2026 was a month of recalibration, not catastrophe. Deal activity continued, capital was deployed, and companies raised funding. But the composition and dynamics shifted meaningfully-and these shifts will define the fundraising environment for the rest of 2026.

For founders currently raising or planning to raise capital, the lessons from January are:

1. Unit economics matter more than growth metrics. Investors are asking harder questions about CAC payback, gross margins, and paths to profitability.

2. Valuation expectations have reset. If you're raising Series A in 2026, expect to be valued at 10-15% lower than comparable companies in mid-2025.

3. Early-stage funding is tight. Seed and Series A rounds are harder to raise. Focus on demonstrating exceptional traction before you start pitching.

4. Infrastructure and biotech are winning sectors. If you're building foundational technology or solving a biotech problem, capital is available. If you're building consumer software or applied AI, you face headwinds.

5. Founder-investor fit matters. Investors are being more selective about who they back. Build genuine relationships and find investors who understand your market and can add real value.

6. Down rounds are normalizing. If your previous round was at an inflated valuation, expect pressure to reprice. This is healthy market behavior, not a personal failure.

For deeper insights on navigating this environment, Capitaly's 10 fundraising myths and 20 must-know angel investor strategies provide essential context for founders building in 2026.

The venture capital market in January 2026 was not broken-it was working. Capital flowed to companies with proven metrics, defensible business models, and clear paths to profitability. This is how efficient capital allocation should work. For founders willing to embrace this reality and build accordingly, the opportunity remains significant.

Conclusion: The Data Behind the Drama

January 2026 will be remembered as the month when the venture capital market finally stopped pretending that growth-at-all-costs was a viable strategy. The data is clear: investors are repricing risk, concentrating capital in later-stage rounds, and demanding proof of unit economics before they write checks.

This is not bad news for founders. It's actually clarifying. The companies that will thrive in 2026 are those building real products for real problems, with clear paths to profitability and sustainable competitive advantages. The companies that will struggle are those chasing narratives, burning capital inefficiently, and hoping that market momentum will carry them to exit.

If you're raising capital in 2026, use January's data as your baseline. Understand where your company fits in the market, what investors are actually funding, and what metrics matter most. Then build accordingly. The founders who embrace this reality-rather than fighting it-will be the ones raising capital with ease in 2026 and beyond.

For ongoing insights into the venture capital market, metrics that matter for fundraising, and tactical advice on navigating the current environment, join Capitaly where founders, operators, and investors share daily insights on capital raising, valuations, and startup life. The market moves fast, and staying informed is essential for making smart decisions about your fundraising strategy.